Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Healthcare Agencies II

Healthcare Agencies II

There are various healthcare agencies in the United States—some of which are managed by religious institutions and others by different government branches.
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources, and lay...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Statin Therapy on the Risk of Stroke Recurrence, Mortality, and Dementia After Ischemic Stroke (ISMARDD Study): A Comprehensive Meta-Analysis.

Neurology international·2025

Same author

Visually-provoked seizures: Consensus of the Epilepsy Foundation Working Group.

Epilepsia·2025

Same author

Comment on Mavroudis et al. Post-Traumatic Epilepsy After Mild and Moderate Traumatic Brain Injury: A Narrative Review and Development of a Clinical Decision Tool. <i>Reports</i> 2025, <i>8</i>, 193.

Reports (MDPI)·2025

Same author

Neuroimaging and Genetic Markers of Cerebral Small Vessel Disease and Cognitive Outcomes: A Systematic Review and Meta-Analysis (NEUROGEN-SVD Study).

Diagnostics (Basel, Switzerland)·2025

Same author

Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.

CNS drugs·2025

Same author

Comparison of Epileptiform Activity in Routine and Sleep-Deprived Electroencephalogram (EEG) Studies: A Five-Year Retrospective Analysis.

Journal of integrative neuroscience·2025

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Doctors and pharmaceutical industry.

Roy G Beran¹

¹University of NSW, Australia.

Medicine and Law

|February 18, 2010

Summary

Pharmaceutical industry support for doctors is scrutinized, questioning if it influences prescribing habits. This analysis explores ethical considerations and potential impacts on medical practice and patient care.

Area of Science:

Medical Ethics
Pharmaceutical Industry Practices
Healthcare Professional Conduct

Background:

The pharmaceutical industry's financial support of physicians, including gifts and travel subsidies, is often perceived negatively.
This perception raises concerns about physician independence, self-interest, and patient-centered care.
Such industry practices are viewed differently in medicine compared to other sectors.

Purpose of the Study:

To examine non-professional conduct in response to pharmaceutical industry inducements.
To critically appraise the relationship between doctors and the pharmaceutical industry.
To evaluate the consequences of these relationships for patient outcomes.

Main Methods:

Review of existing literature on physician-pharmaceutical industry interactions.

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Related Experiment Videos

Last Updated: Jun 16, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Analysis of ethical frameworks concerning conflicts of interest.

Examination of case studies and professional conduct guidelines.

Main Results:

The paper explores the dual nature of pharmaceutical support: potential for educational advancement versus risk of undue influence.
It highlights the lack of clear scientific differentiation between some treatments, complicating prescribing decisions.
The analysis acknowledges that while some physicians may act unethically, not all industry support is inherently improper.

Conclusions:

A critical appraisal of the doctor-pharmaceutical industry relationship is necessary, avoiding automatic condemnation.
Defining non-professional conduct requires careful consideration of conflicts of interest and patient welfare.
Maintaining professional standards and ethical medical practice in the face of industry influence remains a key challenge.